1000303-34-3

Upstream product

• 1245506-77-7 [(3S,4S)-1-benzyl-4-(4-bromobutyrylamino)pyrrolidin-3-yl]carbamic acid tert-butyl ester 
• 75172-31-5 (3R,4R)-1-benzyl-3,4-dihydroxypyrrolidine-2,5-dione 
• 288313-99-5 3,4-Diazido-1-benzylpyrrolidine 
• 100-46-9 benzylamine 
• 90365-74-5 (3S,4S)-(+)-1-benzyl-3,4-pyrrolidinediol 
• 104351-40-8 (3S,4S)-1-benzyl-3,4-pyrrolidinediyl bis(methanesulfonate) 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1293389-12-4 C₁₅H₁₉N₅O 
• 1000303-14-9 (3S,4S)-4-azido-1-benzylpyrrolidin-3-ylamine 
• 1000303-33-2 tert-butyl (3S,4S)-4-(4-chlorobutanamido)-1-benzylpyrrolidin-3-ylcarbamate 

Downstream Products

• 1293389-05-5 C₁₈H₁₈F₃N₅O 

Relevant academic research and scientific papers

1-((3S,4S)-4-Amino-1-(4-substituted-1,3,5-triazin-2-yl) pyrrolidin-3-yl)-5,5-difluoropiperidin-2-one inhibitors of DPP-4 for the treatment of type 2 diabetes

A 3-amino-4-substituted pyrrolidine series of dipeptidyl peptidase IV (DPP-4) inhibitors was rapidly developed into a candidate series by identification of a polar valerolactam replacement for the lipophilic 2,4,5-trifluorophenyl pharmacophore. The additi

COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS

The present invention is directed to therapeutic compotmds of the following formula (I) which have activity as agonists of GPR 119 and are useful for the treatment of metabolic disorders including type II diabetes.

Substituted 3-Amino-Pyrrolidino-4-Lactams

The invention provides compounds of formula (1), and the pharmaceutically acceptable salt thereof, wherein R1, n and R2 are as described herein; compositions thereof; and uses thereof.